Acute Heart Failure Clinical Trial
Official title:
Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels
Post-discharge mortality and re-hospitalization for acute heart failure (AHF) affects 15% and 30% of patients respectively, within 90 days. With over 1 million annual hospitalizations and a financial cost exceeding 20 billion dollars, AHF is a major public health burden. Yet no AHF therapy to date definitively reduces morbidity and mortality, and in stark contrast to heart attack patients, highly rated evidence in guidelines do not exist. Although AHF is a syndrome and not one disease, typical treatment of patients hospitalized with AHF suggests otherwise. Despite substantial differences among AHF patients, therapy is largely uniform; patients receive medicine to help get rid of excess volume and little else. Although decades of empirical use support the symptomatic benefits of traditional therapies, outcomes remain extremely poor. As opposed to the "one-size-fits-all‟ approach used unsuccessfully to date in clinical trials, identification of specific AHF patient sub-groups is critical, so that tailored therapies can be developed and tested. Preliminary data suggests that the neurohormone aldosterone may be detrimental in AHF patients. Furthermore, this hormone level appears to rise during hospitalization. The investigators therefore propose to identify specific AHF patient phenotypes associated with high serum aldosterone levels to subsequently address the hypothesis that early aldosterone blockade continued throughout hospitalization will decrease re-hospitalization and mortality. Specifically, the investigators hypothesize that AHF patients with elevated serum aldosterone levels have a distinct phenotype compared to those with lower or normal aldosterone levels. Specifically, they will be older, have a lower systolic blood pressure, lower EF, worse renal function, higher BNP, and previous hospitalization for HF.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
| Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
| Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
| Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
| Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
| Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
| Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
| Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
| Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
| Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
| Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
| Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
| Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
| Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
| Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
| Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
| Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
| Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
| Recruiting |
NCT04329234 -
Korean Heart Failure Registry III
|